BA
CORT icon

Bridgewater Associates’s Corcept Therapeutics CORT Stock Holding History

Bridgewater Associates’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.01M Buy
57,602
+19,180
+50% +$1.16M 0.02% 482
2026
Q1 		$1.55M Sell
38,422
-240,578
-86% -$9M 0.01% 708
2025
Q4 		$9.71M Sell
279,000
-26,946
-9% -$2.12M 0.04% 364
2025
Q3 		$25.4M Buy
+305,946
New +$22.1M 0.1% 169

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgewater Associates's CORT Position: Q2 2026 in Review

Bridgewater Associates increased its Corcept Therapeutics (CORT) stake by 50% in Q2 2026, buying an estimated $1.16M and bringing the position to 57,602 shares worth $5.01M. The position accounts for 0.02% of the portfolio, ranked #482.

Bridgewater Associates first reported a position in CORT in Q3 2025 and has held it in 4 quarters since. The position peaked at $25.4M in Q3 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Bridgewater Associates held 57,602 shares of Corcept Therapeutics worth $5.01M as of Q2 2026.
  • Bridgewater Associates bought 19,180 Corcept Therapeutics shares in Q2 2026, an estimated $1.16M.
  • Corcept Therapeutics made up 0.02% of Bridgewater Associates's portfolio in Q2 2026, its #482 holding.
  • Bridgewater Associates first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Bridgewater Associates's Corcept Therapeutics position peaked at $25.4M in Q3 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.